Stem Cell Derived Cardiomyocytes in Drug Safety Evaluations: Lessons Learned from the Comprehensive in Vitro Proarrhythmia Assay (CiPA) Initiative.Tuesday, 5 April 2016 at 11:15 Add to Calendar ▼2016-04-05 11:15:002016-04-05 12:15:00Europe/LondonStem Cell Derived Cardiomyocytes in Drug Safety Evaluations: Lessons Learned from the Comprehensive in Vitro Proarrhythmia Assay (CiPA) Initiative.Stem Cells in Drug Discovery 2016 in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com This presentation will describe the critical role of human stem cell derived cardiomyocytes in the CiPA initiative, lessons learned as the project moves towards completion, along with their future role in preclinical cardiac safety testing. |